产品/疗法

与 CAR-T 细胞治疗后感染风险相关的宿主免疫生物标志物

Host immune biomarkers associated with infection risk after CAR T-cell therapy.

纵向免疫分析识别出与感染风险和 CAR-T 相关毒性相关的不同免疫学特征。这些发现提示免疫监测在改善风险分层和指导 CAR-T 治疗后支持治疗方面具有作用。

混合 CAR-T 细胞产品与重叠患者是否会高估 tisagenlecleucel 相关 HLH 风险？

Could Mixed CAR T-Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?

Tisagenlecleucel 用于年轻急性淋巴细胞白血病患者移植后复发：欧洲真实世界结局决定因素

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Tisagenlecleucel 对比标准治疗挽救化疗治疗复发/难治性弥漫大 B 细胞淋巴瘤的真实世界结局：一项来自韩国的倾向性评分匹配分析

Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propen

在这项来自亚洲的真实世界倾向性评分匹配比较中，tisagenlecleucel 在韩国 R/R DLBCL 患者中显示出优于 SOC 挽救化疗的生存和缓解结局，支持其作为 3L 治疗标准方案的地位。

大 B 细胞淋巴瘤 CAR-T 治疗后的缓解动力学：来自 DESCAR-T 登记数据库的 LYSA 研究

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

白细胞单采时外周原始细胞是儿童和年轻成人接受 tisagenlecleucel 后生存的风险因素

Peripheral Blasts at Apheresis as a Risk Factor for Survival following Tisagenlecleucel in Children and Young Adults.

年龄 >70 岁大 B 细胞淋巴瘤患者中 axicabtagene ciloleucel 较 tisagenlecleucel 改善无进展生存期

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

氟达拉滨暴露对大 B 细胞淋巴瘤患者 CAR-T 细胞治疗结局的影响

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

替沙仑赛在儿童复发/难治性 B 细胞急性淋巴细胞白血病中的感染相关不良事件：一项 FAERS 药物警戒研究

Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance S

既往苯达莫司汀暴露对滤泡性淋巴瘤 CAR-T 细胞治疗结局的影响

Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.

滤泡性淋巴瘤：新型疗法与最佳治疗排序策略

Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.

Tisagenlecleucel 在复发/难治性 ALL 儿童及年轻成人患者中的长期临床结局

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.

R/R LBCL 患者 CAR-T 细胞治疗出院后 30 天与 90 天内医疗资源使用增加的相关因素

Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL.

大 B 细胞淋巴瘤中的 CD19 CAR-T 细胞治疗：临床证据、耐药、毒性与精准策略

CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.

儿童 B-ALL 中 CAR-T 后 HLH 样综合征与死亡风险增加及 CD19 阴性复发相关

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

大 B 细胞淋巴瘤 CAR-T 细胞治疗时间改善的驱动因素：一项日本全国注册分析

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Axicabtagene Ciloleucel 与 Tisagenlecleucel 在欧洲大 B 细胞淋巴瘤患者中的疗效和毒性比较：系统综述与荟萃分析

Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic rev

在 LBCL 欧洲患者中，Axi-cel 相比 Tisa-cel 表现出更优的短期疗效，但在某些中期疗效终点上表现较差，且通常与更大的毒性和更高的医疗资源利用相关。CAR-T 方案的选择应个体化，需仔细权衡疗效、毒性和成本。未来需要随访时间更长的高质量研究来评估长期结局并验证本分析的结果。

CAR-T 细胞治疗后的免疫效应细胞相关血液毒性：来自大型国家数据库的见解

Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.

CAR-T 细胞治疗的真实世界皮肤不良事件：FDA 不良事件报告系统十年期不成比例分析

Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System.

B 细胞淋巴瘤 CAR-T 细胞治疗后的十年结局

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

在接受过重度预治疗的 B 细胞非霍奇金淋巴瘤患者中，单次输注 tisagenlecleucel 使约三分之一的大 B 细胞淋巴瘤患者和近半数的滤泡性淋巴瘤患者获得了长达十年的缓解（无淋巴瘤生存）。